Advertisement


Karl Lewis, MD, on Basal Cell Carcinoma: An Ongoing Study

ESMO 2018 Congress

Advertisement

Karl Lewis, MD, of the University of Colorado, discusses a phase II study of cemiplimab in patients with advanced basal cell carcinoma who experienced progression of disease on, or were intolerant of, prior hedgehog pathway inhibitor therapy.
For more information about this ongoing trial, visit clinicaltrials.gov
ClinicalTrials.gov ID: NCT03132636



Related Videos

Lung Cancer
Immunotherapy

Suresh S. Ramalingam, MD, on Lung Cancer: Research Highlights

Suresh S. Ramalingam, MD, of the Emory University School of Medicine, summarizes the top-line lung cancer results reported at this year’s ESMO Congress, including the role of targe...

Skin Cancer
Symptom Management

Paolo A. Ascierto, MD, on Melanoma: Acute and Chronic Toxicities

Paolo A. Ascierto, MD, of Istituto Nazionale Tumori–Fondazione Pascale, discusses the breakthroughs in melanoma treatment and the challenges of managing toxicities, especiall...

Geriatric Oncology
Immunotherapy

Matti S. Aapro, MD, on Immunotherapy in Older Patients

Matti S. Aapro, MD, of the Genolier Cancer Centre, discusses the optimal treatment and supportive care for older patients with cancer, including the importance of maintaining...

Issues in Oncology
Immunotherapy
Symptom Management

Caroline Robert, MD, PhD, on Immunotherapy Toxicities: Expert Perspective

Caroline Robert, MD, PhD, of Gustave Roussy Cancer Centre, discusses managing toxicities of immunotherapy, including neurotoxicity, and treating beyond acute adverse events.

Lung Cancer
Immunotherapy

Tony Mok, MD, on NSCLC: Targeted Treatment Update

Tony Mok, MD, of the Chinese University of Hong Kong, discusses two important studies in non–small cell lung cancer: FLAURA, which looked at the first-line activity of osimertinib ...

Advertisement

Advertisement



Advertisement